Novartis posted H1 2025 net sales of USD 27.3 billion, up 13% year-on-year, driven by strong performances in oncology and cardiovascular therapies. Key growth drivers included Kisqali (ribociclib, +60%), Leqvio (inclisiran, +66%), and Pluvicto (¹⁷⁷Lu vipivotide tetraxetan), with oncology sales reaching USD 8.2 billion (+22%). Entresto (sacubitril + valsartan) grew 22% to USD 4.6 billion but faces upcoming US patent expiry and pricing pressures.

In immunology, Cosentyx (secukinumab) rose 11% to USD 3.2 billion despite biosimilar competition. Kesimpta (ofatumumab) surged 38% in multiple sclerosis, while Fabhalta (iptacopan) for rare kidney diseases reached USD 201 million. Novartis expects full-year mid-to-high single-digit growth, supported by recent launches like Vanrafia (atrasentan) and upcoming data for zigakibart in IgA nephropathy. The company also highlighted Pluvicto's potential expansion into earlier prostate cancer stages following positive Phase III results.

According to PharmCube's NextBiopharm® database, Kisqali sales (image below) have expanded continuously since its 2017 launch, the oncology drug enjoying blockbuster status since 2022. Click here to request a free trial for NextBiopharm®.